A Progressively Disassembled DNA Repair Inhibitors Nanosystem for the Treatment of BRCA Wild-Type Triple-Negative Breast Cancer

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750–1769. doi:10.1016/S0140-6736(20)32381-3
   PubMed Web of Science ®Google Scholar
• Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91–113. doi:10.1038/s41571-021-00565-2
   PubMed Web of Science ®Google Scholar
• Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–690. doi:10.1038/nrclinonc.2016.66
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast Cancer Treatment: a Review. JAMA. 2019;321:288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Nedeljkovic M, Damjanovic A. Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019;8. doi:10.3390/cells8090957
   PubMed Web of Science ®Google Scholar
• Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24:157–167. doi:10.1038/modpathol.2010.200
   PubMed Web of Science ®Google Scholar
• Caramelo O, Silva C, Caramelo F, et al. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis. Hered Cancer Clin Pract. 2022;20:34. doi:10.1186/s13053-022-00242-0
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921. doi:10.1038/nature03445
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917. doi:10.1038/nature03443
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–1158. doi:10.1126/science.aam7344
   PubMed Web of Science ®Google Scholar
• Sargazi S, Saravani R, Zavar Reza J, et al. Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells. Iran Biomed J. 2019;23:312–323. doi:10.29252/.23.5.312
   PubMedGoogle Scholar
• Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34:360–394. doi:10.1101/gad.334516.119
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012;72:5588–5599. doi:10.1158/0008-5472.CAN-12-2753
   PubMed Web of Science ®Google Scholar
• Patel M, Nowsheen S, Maraboyina S, Xia F. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell Biosci. 2020;10:35. doi:10.1186/s13578-020-00390-7
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523–533. doi:10.1056/NEJMoa1706450
   PubMed Web of Science ®Google Scholar
• Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32:240–249. doi:10.1016/j.annonc.2020.11.009
   PubMed Web of Science ®Google Scholar
• Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707–714. doi:10.1007/s10549-014-2980-0
   PubMed Web of Science ®Google Scholar
• Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–2795. doi:10.1002/cncr.26576
   PubMed Web of Science ®Google Scholar
• Evans KW, Yuca E, Akcakanat A, et al. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017;23:6468–6477. doi:10.1158/1078-0432.CCR-17-0615
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–861. doi:10.1016/S1470-2045(11)70214-5
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245–251. doi:10.1016/S0140-6736(10)60893-8
   PubMed Web of Science ®Google Scholar
• Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022;31:607–631. doi:10.1080/13543784.2022.2067527
   PubMed Web of Science ®Google Scholar
• Dong Y, Liao H, Fu H, et al. pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer. ACS Appl Mater Interfaces. 2019;11:38417–38428. doi:10.1021/acsami.9b12140
   PubMed Web of Science ®Google Scholar
• Yusoh NA, Tiley PR, James SD, et al. Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy. J Med Chem. 2023;66:6922–6937. doi:10.1021/acs.jmedchem.3c00322
   PubMed Web of Science ®Google Scholar
• Wang C, Qu L, Li S, et al. Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA. J Med Chem. 2021;64:12630–12650. doi:10.1021/acs.jmedchem.1c00567
   PubMed Web of Science ®Google Scholar
• Yusoh NA, Leong SW, Chia SL, et al. Metallointercalator [Ru(dppz)(2)(PIP)](2+) Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition. ACS Chem Biol. 2020;15:378–387. doi:10.1021/acschembio.9b00843
   PubMed Web of Science ®Google Scholar
• Luo ML, Zheng F, Chen W, et al. Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition. Cancer Res. 2020;80:3033–3045. doi:10.1158/0008-5472.CAN-19-2739
   PubMed Web of Science ®Google Scholar
• Zhou J, Gelot C, Pantelidou C, et al. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nat Cancer. 2021;2:598–610. doi:10.1038/s43018-021-00203-x
   PubMedGoogle Scholar
• Ceccaldi R, Liu JC, Amunugama R, et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. Nature. 2015;518:258–262. doi:10.1038/nature14184
   PubMed Web of Science ®Google Scholar
• Mateos-Gomez PA, Gong F, Nair N, et al. Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination. Nature. 2015;518:254–257. doi:10.1038/nature14157
   PubMed Web of Science ®Google Scholar
• Davodabadi F, Mirinejad S, Fathi-Karkan S, et al. Aptamer-functionalized quantum dots as theranostic nanotools against cancer and bacterial infections: a comprehensive overview of recent trends. Biotechnol Prog. 2023:e3366. doi:10.1002/btpr.3366
   PubMed Web of Science ®Google Scholar
• Razlansari M, Jafarinejad S, Rahdar A, et al. Development and classification of RNA aptamers for therapeutic purposes: an updated review with emphasis on cancer. Mol Cell Biochem. 2023;478:1573–1598. doi:10.1007/s11010-022-04614-x
   PubMed Web of Science ®Google Scholar
• Vallet-Regi M, Schuth F, Lozano D, Colilla M, Manzano M. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem Soc Rev. 2022;51:5365–5451. doi:10.1039/d1cs00659b
   PubMed Web of Science ®Google Scholar
• Wang D, Nie T, Huang C, et al. Metal-Cyclic Dinucleotide Nanomodulator-Stimulated STING Signaling for Strengthened Radioimmunotherapy of Large Tumor. Small. 2022;18:e2203227. doi:10.1002/smll.202203227
   PubMed Web of Science ®Google Scholar
• Zeng L, Wang H, Shi W, et al. Aloe derived nanovesicle as a functional carrier for indocyanine green encapsulation and phototherapy. J Nanobiotechnology. 2021;19:439. doi:10.1186/s12951-021-01195-7
   PubMed Web of Science ®Google Scholar
• Shi L, Jin Y, Lai S, et al. Redox-responsive carrier based on fluorinated gemini amphiphilic polymer for combinational cancer therapy. Colloids Surf B Biointerfaces. 2022;216:112551. doi:10.1016/j.colsurfb.2022.112551
   PubMed Web of Science ®Google Scholar
• Guo J, De May H, Franco S, et al. Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns. Nat Biomed Eng. 2022;6:19–31. doi:10.1038/s41551-021-00795-w
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang M, Zhang Y, et al. Intraparticle Double-Scattering-Decoded Sonogenetics for Augmenting Immune Checkpoint Blockade and CAR-T Therapy. Adv Sci. 2022;9:e2203106. doi:10.1002/advs.202203106
   Web of Science ®Google Scholar
• You Y, Zhao Z, He L, et al. Long‐Term Oxygen Storage Nanosystem for Near‐Infrared Light‐Triggered Oxygen Supplies to Antagonize Hypoxia‐Induced Therapeutic Resistance in Nasopharyngeal Carcinoma. Adv Funct Mater. 2020;30. doi:10.1002/adfm.202002369
   PubMed Web of Science ®Google Scholar
• Yang Y, Sun B, Zuo S, et al. Trisulfide bond-mediated doxorubicin dimeric prodrug nanoassemblies with high drug loading, high self-assembly stability, and high tumor selectivity. Sci Adv. 2020;6. doi:10.1126/sciadv.abc1725
   Web of Science ®Google Scholar
• Li S, Saw PE, Lin C, et al. Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy. Biomaterials. 2020;234:119760. doi:10.1016/j.biomaterials.2020.119760
   PubMed Web of Science ®Google Scholar
• Wu J, Williams GR, Niu S, et al. A Multifunctional Biodegradable Nanocomposite for Cancer Theranostics. Adv Sci. 2019;6:1802001. doi:10.1002/advs.201802001
   Web of Science ®Google Scholar
• Li J, Xu R, Lu X, He J, Jin S. A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance. Int J Nanomedicine. 2017;12:8043–8056. doi:10.2147/IJN.S148273
   PubMed Web of Science ®Google Scholar
• Chen W, Glackin CA, Horwitz MA, Zink JI. Nanomachines and Other Caps on Mesoporous Silica Nanoparticles for Drug Delivery. Acc Chem Res. 2019;52:1531–1542. doi:10.1021/acs.accounts.9b00116
   PubMed Web of Science ®Google Scholar
• Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134:489–492. doi:10.1093/jn/134.3.489
   PubMed Web of Science ®Google Scholar
• Zhao Q, Geng H, Wang Y, et al. Hyaluronic acid oligosaccharide modified redox-responsive mesoporous silica nanoparticles for targeted drug delivery. ACS Appl Mater Interfaces. 2014;6:20290–20299. doi:10.1021/am505824d
   PubMed Web of Science ®Google Scholar
• Dhoonmoon A, Nicolae CM, Moldovan GL. The KU-PARP14 axis differentially regulates DNA resection at stalled replication forks by MRE11 and EXO1. Nat Commun. 2022;13:5063. doi:10.1038/s41467-022-32756-5
   PubMed Web of Science ®Google Scholar
• Hijaz M, Chhina J, Mert I, et al. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. Gynecol Oncol. 2016;142:323–331. doi:10.1016/j.ygyno.2016.06.005
   PubMed Web of Science ®Google Scholar
• Wu Z, Bai Y, Jin J, et al. Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer. Eur J Med Chem. 2021;217:113357. doi:10.1016/j.ejmech.2021.113357
   PubMed Web of Science ®Google Scholar
• Liu Q, Gheorghiu L, Drumm M, et al. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene. 2018;37:2793–2805. doi:10.1038/s41388-018-0130-6
   PubMed Web of Science ®Google Scholar
• Zhang N, Huang L, Tian J, et al. A novel synthetic novobiocin analog, FM-Nov17, induces DNA damage in CML cells through generation of reactive oxygen species. Pharmacol Rep. 2016;68:423–428. doi:10.1016/j.pharep.2015.11.002
   PubMed Web of Science ®Google Scholar
• Wu L, Chen X, Huang L, et al. A Novobiocin Derivative, XN4, Inhibits the Proliferation of Chronic Myeloid Leukemia Cells by Inducing Oxidative DNA Damage. PLoS One. 2015;10:e0123314. doi:10.1371/journal.pone.0123314
   PubMed Web of Science ®Google Scholar
• Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24:679–686. doi:10.1038/leu.2010.6
   PubMed Web of Science ®Google Scholar
• Lee Y, Wang Q, Shuryak I, Brenner DJ, Turner HC. Development of a high-throughput gamma-H2AX assay based on imaging flow cytometry. Radiat Oncol. 2019;14:150. doi:10.1186/s13014-019-1344-7
   PubMed Web of Science ®Google Scholar
• Liu D, He H, Kong F, et al. A versatile metal–organic nanoplatform in combination with CXCR4 antagonist and PD-L1 inhibitor for multimodal synergistic cancer therapy and MRI-guided tumor imaging. Nano Today. 2022;47. doi:10.1016/j.nantod.2022.101689
   Web of Science ®Google Scholar
• Ren J, Tang X, Wang T, et al. A Dual-Modal Magnetic Resonance/Photoacoustic Imaging Tracer for Long-Term High-Precision Tracking and Facilitating Repair of Peripheral Nerve Injuries. Adv Healthc Mater. 2022;11:e2200183. doi:10.1002/adhm.202200183
   PubMed Web of Science ®Google Scholar
• Wang D, Zhou J, Fang W, et al. A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer. Bioact Mater. 2022;13:312–323. doi:10.1016/j.bioactmat.2021.10.046
   PubMed Web of Science ®Google Scholar
• Xiao Z, You Y, Liu Y, et al. NIR-Triggered Blasting Nanovesicles for Targeted Multimodal Image-Guided Synergistic Cancer Photothermal and Chemotherapy. ACS Appl Mater Interfaces. 2021;13:35376–35388. doi:10.1021/acsami.1c08339
   PubMed Web of Science ®Google Scholar
• Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst. 2000;92:242–248. doi:10.1093/jnci/92.3.242
   PubMed Web of Science ®Google Scholar
• Ghosh S, Liu Y, Garg G, et al. Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail. ACS Med Chem Lett. 2016;7:813–818. doi:10.1021/acsmedchemlett.6b00224
   PubMed Web of Science ®Google Scholar
• Calderwood SK, Gong J. Heat Shock Proteins Promote Cancer: it’s a Protection Racket. Trends Biochem Sci. 2016;41:311–323. doi:10.1016/j.tibs.2016.01.003
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades CS, Laubach JP, et al. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011;152:367–379. doi:10.1111/j.1365-2141.2010.08360.x
   PubMed Web of Science ®Google Scholar
• Zhang PC, Liu X, Li MM, et al. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1alpha/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo. Biochem Pharmacol. 2020;172:113771. doi:10.1016/j.bcp.2019.113771
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu J, Jin Y, et al. Copper(I) Phosphide Nanocrystals for In Situ Self‐Generation Magnetic Resonance Imaging‐Guided Photothermal‐Enhanced Chemodynamic Synergetic Therapy Resisting Deep‐Seated Tumor. Adv Funct Mater. 2019;29. doi:10.1002/adfm.201904678
   Web of Science ®Google Scholar
• Khan M, Boumati S, Arib C, et al. Doxorubicin (DOX) Gadolinium-Gold-Complex: a New Way to Tune Hybrid Nanorods as Theranostic Agent. Int J Nanomedicine. 2021;16:2219–2236. doi:10.2147/IJN.S295809
   PubMed Web of Science ®Google Scholar
• Shi C, Liu D, Xiao Z, et al. Monitoring Tumor Response to Antivascular Therapy Using Non-Contrast Intravoxel Incoherent Motion Diffusion-Weighted MRI. Cancer Res. 2017;77:3491–3501. doi:10.1158/0008-5472.CAN-16-2499
   PubMed Web of Science ®Google Scholar
• Sheng Y, Dang X, Zhang H, et al. Correlations between intravoxel incoherent motion-derived fast diffusion and perfusion fraction parameters and VEGF- and MIB-1-positive rates in brain gliomas: an intraoperative MR-navigated, biopsy-based histopathologic study. Eur Radiol. 2023. doi:10.1007/s00330-023-09506-2
   Web of Science ®Google Scholar
• Lee KJ, Mann E, Wright G, et al. Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. Ther Adv Med Oncol. 2020;12:1758835920958354. doi:10.1177/1758835920958354
   Web of Science ®Google Scholar
• Chowdhury P, Nagesh PKB, Hatami E, et al. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. J Colloid Interface Sci. 2019;535:133–148. doi:10.1016/j.jcis.2018.09.072
   PubMed Web of Science ®Google Scholar
• Sargazi S, Kooshkaki O, Zavar Reza J, et al. Mild antagonistic effect of Valproic acid in combination with AZD2461 in MCF-7 breast cancer cells. Med J Islam Repub Iran. 2019;33:29. doi:10.34171/mjiri.33.29
   PubMedGoogle Scholar
• Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1:315–322. doi:10.1002/emmm.200900041
   PubMed Web of Science ®Google Scholar
• Siminzar P, Tohidkia MR, Eppard E, et al. Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment. Mol Imaging Biol. 2023;25:464–482. doi:10.1007/s11307-022-01795-1
   PubMed Web of Science ®Google Scholar
• Alikhanzadeh-Arani S, Almasi-Kashi M, Sargazi S, et al. CoNiZn and CoNiFe Nanoparticles: synthesis, Physical Characterization, and In Vitro Cytotoxicity Evaluations. Appl Sci. 2021;11. doi:10.3390/app11125339
   Google Scholar